The blood testing equipment market is poised for significant growth between 2025 and 2035, driven by increasing demand for diagnostic tools, rising prevalence of chronic and infectious diseases, and advancements in testing technology. The market is expected to witness robust expansion due to an aging population, growing awareness of preventive healthcare, and the expansion of point-of-care testing solutions.
With continuous improvements in automation, portability, and accuracy, the market is projected to register a size of USD 96.8 billion in 2025 and is expected to reach around USD 135.0 billion by 2035, indicating a CAGR of 6.8% over the forecast period.
Market for blood testing equipment bears a significant impact due to a number of transformative trends. The shift toward decentralized and home-based testing solutions, especially with the rapid point-of-care (POC) devices that are now more easily adopted. Automation in the laboratories and machine learning data processing are among the factors that are pushing the testing efficiency and exactness even further.
Besides, the increasing global prevalence of health problems including diabetes, cardiovascular, and communicable diseases makes the need for dependable diagnostic tools escalate. Regulatory initiatives, which are promoting the early diagnosis of diseases as well as personalized medicine, are also contributing highly to the market growth.
The rising concentration on minimally invasive testing and microfluidics is alleviating patient stress and boosting their cooperation. Additionally, the influx of networked health solutions and digital diagnostics is making real-time monitoring and data-driven choices possible, which is very helpful in controlling chronic diseases.
| Metric | Value |
|---|---|
| Industry Size (2025E) | USD 96.8 billion |
| Industry Value (2035F) | USD 135.0 billion |
| CAGR (2025 to 2035) | 6.88% |
Artificial Intelligence revolutionizes blood analysis with the advancement of precision and minimizing human error. AI-oriented algorithms have now advanced to the point where they can retrieve information pertaining to diseases like leukaemia, sepsis, and diabetes-related issues with more than 90% accuracy.
With constant improvement in technology, the incorporation of AI will optimize internal operating systems, leading to shorter drafts, and decreased per-test costs; clinical and home-testing sectors will flourish in the process.
The adoption of microfluidic-based lab-on-a-chip devices is a dynamic transformer of blood testing that works by lowering the sample volume needed and enhancing the portability. LOC technology offers point-of-care activities with results in mere 15 minutes and this is the reason for it being a must-have in the emergency room and remote healthcare services. The growing interest in telemedicine and decentralized care will come together to foster its application further in the next few years.
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
The North American blood testing equipment market is now showing a distinctive shift toward the home-based diagnostic segment; and this is largely due to the more than 60% of healthcare providers who are already using remote patient monitoring functions. The USA FDA's endorsement of revolutionary products for blood tests such as microfluidic systems with technologies similar to Theranos is driving the market towards greater reach. It also worth saying that the increased incidence of chronic diseases in the region is a convincing reason for the need for superior diagnostic instruments.
The growing number of people with diabetes and cardiovascular disorders in North America is a primary factor in the increased desire for continuous glucose monitoring (CGM) and lipid profile tests. Statistics show that CGM use is going up a lot because now there are 37 million Americans who have been diagnosed with diabetes. The market is also likely to increasingly grow as insurance companies are expanding their plans to cover home diagnostics and telehealth services.
Changes in laws that are in favour of genomic medicine and biomarker-based diagnostics are fast-tracking the introduction of new blood testing technologies. The NIH’s fundings channelled into the liquid biopsy study have the potential to redirect the market from major surgery to early cancer screenings with non-invasive methods. Besides the AI in Diagnostics drive, the government funding will still be the prime mover of shaping the market in North America.
The European blood testing equipment market is driven by stringent regulations emphasizing patient safety and diagnostic accuracy. The EU's in Vitro Diagnostic Regulation (IVDR) has set higher standards for blood testing devices, leading to increased investments in compliance-driven innovation. This regulatory landscape is pushing manufacturers to focus on precision-driven, AI-enhanced diagnostic tools.
Germany and the UK are leading the market with strong R&D investments in personalized medicine and early disease detection. The growing adoption of digital pathology and AI-assisted hematology analyzers is transforming diagnostic efficiency. With the European Commission allocating €2 billion toward AI in healthcare, the blood testing sector is expected to benefit significantly.
The rising geriatric population across Europe is increasing demand for routine blood tests, particularly for managing chronic conditions like anemia and cardiovascular diseases. Over 20% of the EU population is aged 65 and older, making blood diagnostics a critical component of preventive healthcare strategies, fueling market growth.
The Asia-Pacific area is experiencing a noticeable demand rise for blood testing devices due to the increased healthcare availability in remote areas. The schemes of the government such as India Ayushman Bharat and China Healthy China 2035 are developing the diagnostic infrastructure, and in this way, the acquisition of blood tests has become more common and chiefly available to more population groups.
The region's growing biotech field is the root of the development of blood testing, especially in the areas of genetic screening and infectious disease diagnostics. Just China on its own is responsible for more than 40% of the world hepatitis B cases which consequently results in the need for precision immunoassay analysers. At the same time, Japan, as the leading country in the microfluidics field, is making a significant impact on the point-of-care testing of diseases.
Medical tourism in Asia-Pacific is a significant contributor to the demand for advanced blood testing equipment. Nations such as Thailand, India, and Malaysia are luring in tourists, for the most part, to afford them the pleasure of having quality medical treatment at a much lower cost. The tendency towards disease diagnostics coming to the forefront in private hospitals is also another reason for market expansion.
Challenges
Regulatory Hurdles Slowing Product Approvals
The introduction of new blood testing devices into the market is mainly affected by strict regulatory policies, for instance, the EU's IVDR and the USA FDA's changing compliance conditions. The complicated validation procedure can lead to a product approval delay of 12 to 24 months which, in turn, increases the costs for the manufacturers and makes fewer innovations available.
The requirement for extensive clinical trials and documentation is a great hindrance for the companies that are trying to come up with new testing technologies. Several start-ups deal with financial constraints in terms of fulfilling compliance requirements, thus making the market stagnant in terms of innovation. Nevertheless, regulatory authorities are looking at the possible adoption of adaptive approval pathways to alleviate the bottleneck.
High Cost of Advanced Testing Technologies
The blood testing devices with the latest technology like AI integrated haematology analysers along with molecular diagnostics often are pretty expensive. These costs act as a limiting factor in low-income areas where affordability remains a major issue. For instance, the molecular diagnostic platforms which number over the mark of USD 100,000 to secure them in small laboratories.
The endeavour of creating affordable options like paper-based diagnostics and smartphone-enabled blood tests is gaining momentum. But it is still a challenge to scale them while ensuring precision and quality assurance according to the government body's regulations. The industry partners are channelling resources into local assembly lines as a way to cut down costs and make products more affordable.
Opportunities
Expansion of Liquid Biopsy in Cancer Diagnostics
Liquid biopsy is becoming a revolutionary tool in the fight against cancer with the ability to detect the disease earlier through blood tests without surgery. Companies like Guardant Health and Roche have positioned themselves at The forefront of circulating tumor DNA (ctDNA) analysis which has proven over 85% accuracy in detecting multiple types of cancer. As precision oncology continues to develop, the demand for liquid biopsy technology will increase exponentially.
Regular usage in the clinic for instance, the elimination of certain biopsy types by liquid biopsy is the expectation that the latter will be recognized as the standard process thus leading to the decrease of discomfort of patients and the time taken for diagnosis. The increase in this type of technology during regular check-ups and treatment monitoring will be the prime mover in the blood testing tools market growth during the following ten years.
Wearable Biosensors for Continuous Monitoring
The emergence of wearable biosensors that can provide information about blood composition in real-time is creating diagnostic market opportunities. Wearable devices like glucose monitoring smartwatches and AI-integrated haemoglobin trackers are indicating a transformation in patient monitoring. Research work by Stanford University has shown that biosensors can observe metabolic variations long before the results of the normal laboratory tests are out, projecting 48 hours of lead time.
As the wearable devices empower, the integration of these biosensors with the telehealth platforms will provide personalized healthcare at the perimeter. Such breakthroughs will target the demand for monitoring devices using remote access, especially amongst the patient group with diabetes and cardiovascular diseases, thus heralding a new era of proactive diagnostics.
The blood testing equipment market has experienced significant growth driven by the development of diagnostic technology, the increasing prevalence of chronic diseases and the growth of demand for rapid testing solutions. The COVID-19 pandemic has led to a further drive in the adoption of automated and point-of-care blood testing solutions to boost diagnostic efficiency and lower patient contact.
Regulatory changes and a shift towards personalized medicine have also played a very important part in the process of reshaping the market. In the next decade, from 2025 to 2035, the growth of the industry will be characterized by enacting artificial intelligence, portable diagnostic devices, and the discovery of new biomarkers. The growth of the blood testing market will be backed by the ongoing trend of home-based, cost-effective, and highly accurate blood testing technologies.
The blood testing equipment market is ready for high growth in the next decade, with the merging of digital health, biotechnology, and artificial intelligence as the main drivers. Countries with growing economies will be instrumental in- aiding the access to cheap diagnostic resources that are crafted for low-income parts of the world.
AI analysis will mark the era of accurate and efficient diagnostics while decentralized testing will cuts healthcare infrastructure cost. The constant creation of wearable blood testing device will bring forth real-time health monitoring, providing patients with tailored and proactive healthcare options.
Also, the drive towards sustainability will impact the choice of materials and the production processes, which in turn will make blood testing greener. The regulatory guidelines will be modified to align with the new technologies thus guaranteeing higher accuracy levels and data protection rights. By 2035, the blood testing equipment sector will be thoroughly integrated, efficient, and patient-oriented, setting new records for diagnostic accuracy and accessibility.
| Market Shift | 2020 to 2024 |
|---|---|
| Regulatory Landscape | Increased FDA approvals for rapid testing devices and stricter compliance requirements for laboratory testing. |
| Technological Advancements | Growth in automation and digital blood analysis tools, integration of cloud-based reporting. |
| Industry-Specific Demand | High demand in hospitals, diagnostic labs, and research institutions. |
| Sustainability & Circular Economy | Initial efforts towards reducing waste in disposable testing kits and improving recyclability. |
| Production & Supply Chain | Challenges in raw material sourcing, supply chain disruptions due to COVID-19. |
| Market Growth Drivers | Increased need for rapid diagnostics, high prevalence of diabetes, cardiovascular diseases, and infectious diseases. |
| Market Shift | 2025 to 2035 |
|---|---|
| Regulatory Landscape | Stricter global regulations promoting data accuracy, security, and integration of AI-driven diagnostics. |
| Technological Advancements | Expansion of AI-powered diagnostics, biosensors, and real-time blood monitoring devices. |
| Industry-Specific Demand | Rising home-testing kits and wearable diagnostics for chronic disease management. |
| Sustainability & Circular Economy | Greater emphasis on biodegradable test components and sustainable manufacturing. |
| Production & Supply Chain | More localized production, AI-driven forecasting for raw material sourcing, and 3D-printed test components. |
| Market Growth Drivers | Growing aging population, expansion of telemedicine, and precision medicine influencing next-gen blood testing technologies. |
The increase in demand for personalized medicine and precision diagnostic techniques is the main factor affecting the USA blood testing equipment market. The growing use of telemedicine and home-based diagnostic solutions is making a monumental difference in patient care.
The further funding and partnership arrangement of biotech firms with healthcare companies are the reasons for innovation being boosted. The increase in use of molecular diagnostics has carried out the early detection and precise treatment of diseases. The market is also getting benefitted from the high occurrence of lifestyle diseases such as obesity and hypertension.
Market Growth Factors
| Country | CAGR (2025 to 2035) |
|---|---|
| USA | 5.3% |
The infusion of government initiatives mainly based on preventive health care, and early detection of diseases is the main reason for the rapid growth of the blood testing market of the United Kingdom. Use of the AI-based diagnostics instrument is streamlining the laboratory process and boosting the accuracy of testing.
The increasing public knowledge about the significance of health surveillance is the primary factor for the upsurge in home testing kits. The ongoing movement towards decentralized healthcare is the push factor for the establishment of many community diagnostic centers. Moreover, blood biomarker research investments are leading to the advent of non-invasive diagnostic technologies.
Market Growth Factors
| Country | CAGR (2025 to 2035) |
|---|---|
| UK | 5.9% |
Strict regulatory requirements related to quality and safety are the main driving factor for the EU market. The growing need for point-of-care testing in hospitals and clinics is robustly improving the speed of test and treatment decisions. The increasing share of the elderly population who suffer from age-related diseases like routine blood testing.
Environmentally friendly and waste-free medical devices are on the rise due to the implementation of stricter environmental rules. Furthermore, the strong public health system is the one that facilitates the access to diagnostic services.
Market Growth Factors
| Region | CAGR (2025 to 2035) |
|---|---|
| European Union | 6.2% |
Japan's blood testing equipment market is showing significant growth owing to the progress made in the field of compact and wearable diagnostic devices. The government's strong encouragement of the preventive health sector is elevating the incidence of testing for serious diseases. The concern with the automation of laboratories through robotics is enhancing the tempo and precision of tests. The requirements for COVID-19 protocols are driving the demand for quick and high-throughput diagnostic testing. In addition, the increasing funds flinging into the arena of regenerative medicine are facilitating the path for the development of cutting-edge blood therapies.
Market Growth Factors
| Country | CAGR (2025 to 2035) |
|---|---|
| Japan | 6.5% |
The South Korean blood testing equipment sector is thriving amid the rapid digitalization process of the healthcare infrastructure. The government is earning praises for its active and positive engagement in supporting biotech startups, which in turn is promoting intra-entrepreneurship in the field of diagnosis. The increasing prevalence of blockchain technology has made it possible to manage medical data in a secure and transparent way that is ensuring diagnostic records safety. Also, the growing interest in personalized medicine has caused the need for specific and genetic blood tests to rise.
Market Growth Factors
| Country | CAGR (2025 to 2035) |
|---|---|
| South Korea | 5.5% |
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
Analysers, which are comprised of haematology and biochemical analysers, are blood testing equipment market wherein they dominate much due to their vital role. These machines are favoured by medical professionals for diagnosing anemia, diabetes, and infectious diseases because they render results that are both precise and rapid.
The construction and deployment of these instruments in hospitals, medical laboratories, and research centers are supported by the fact they are accurate and efficient. The FDA and CE regulatory bodies predictively demand the strict conformity of norms to offer safety and reliability that these devices are to commit to, thereby amplifying their credibility.
Analysers in the market have North America and Europe who are still leading in terms of the demand for analysers because of their excellent healthcare infrastructure while Asia-Pacific is on the rise, since the healthcare investments and diagnostic services have increased.
Point-of-care blood testing equipment, which features glucose monitors and haemoglobin meters, is one of the quickest growing segments in the market due to its portability and instant results. These devices were particularly beneficial for chronic illnesses like diabetes and cardiovascular disorders as they give the chance for immediate intervention.
The use of POC devices has also seen a dramatic rise due to the increasing burden of lifestyle-related illnesses and the focus on non-patient specific healthcare. However, the issues that these gadgets face come from the fact that their reliability, value, and integration in resource-limited places rise with technological developments.
Patient-centric healthcare development, increased healthcare access, and consumer awareness of the benefits of early disease detection and monitoring are among the main mainstays of the POC devices market in Asia-Pacific and Latin America.
Hospitals and diagnostic laboratories are the main users of blood testing machines, thanks to their dependency on accurate and timely diagnostics; they account for a big share in the market. As the number of patients increases and the importance the healthcare facilities are putting on guidelines is based on evidence, they are investing in new technologies for diagnosis.
The strict implementation of the protocols and quality control guarantees significantly drive the adoption of the latest blood testing devices. North America and Western Europe are the foremost regions in the market due to their mature healthcare systems, even though developing nations are making a catch-up by building up proper investments in healthcare infrastructure and laboratory capacities to address patient demand.
The huge demand for portable blood-testing devices is driven by the rise of the home and ambulatory-focused healthcare model. The older population, and the more focus on self-monitoring and preventive care, has, in turn, resulted in significant demand for easy-to-use diagnostic tools that people can use without professional assistance.
However, issues like affordability, the precision of devices, and the need for proper patient education still remain as barriers to mass adoption. The future market trends are likely to see a shift to the wearable blood-testing technologies and to the extent of telehealth integration, which are going to further revolutionize diagnostics outside traditional healthcare settings.
The worldwide Blood Testing Equipment Market has ongoing competition as it is fueled by quick innovations in the diagnostic area as well as by the increasing occurrence of chronic diseases and the growing wish for more point-of-care tests. The leading firms are informed taste of the market thanks to the renewal within automated analyzers, wearable diagnostics, and AI-powered testing solutions. Together with the environment issue's concerns and regulatory compliance, the companies' tactics are environmentally sustainable.
The market is consolidating through mergers and acquisitions (M&A) as companies expand their portfolios and areas. Besides, new players are coming up with disruptive technologies, which makes competition tougher.
Market Share Analysis by Company
| Company Name | Estimated Market Share (%) |
|---|---|
| Abbott Laboratories | 18% to 22% |
| Roche Diagnostics | 16% to 20% |
| Siemens Healthineers | 14% to 18% |
| Danaher Corporation | 10% to 14% |
| Thermo Fisher Scientific | 8% to 12% |
| Other Companies (combined) | 30% to 40% |
| Company Name | Key Offerings/Activities |
|---|---|
| Abbott Laboratories | Develops rapid point-of-care blood testing solutions for hospitals and clinics. |
| Roche Diagnostics | Provides high-throughput and AI-powered blood analyzers for laboratory diagnostics. |
| Siemens Healthineers | Specializes in automated immunoassay and haematology analyzers for precision medicine. |
| Danaher Corporation | Focuses on molecular diagnostics and biomarker-based blood testing technologies. |
| Thermo Fisher Scientific | Offers lab instruments, reagent solutions, and liquid biopsy innovations. |
Abbott Laboratories
Abbott Laboratories is the fastest point-of-care blood testing company that brings diagnostics closer to patients around the world. The company's i-STAT system is a widely-used hospital device for real-time results. The company discusses issues of affordability and accuracy and strongly emphasizes the integration of AI to achieve this. Lately, investments are concentrated in midstream markets throughout the world.
Roche Diagnostics
Roche Diagnostics dominates the AI-based blood analyzers and high-throughput testing platforms. It has started automated machines, as well as digital healthcare tools, as an extraordinary level to implement the systems. The group is directly involved by reducing reagent waste and promoting sustainability. Countering arrows to competition involve integrating the utilization of analytics that are based in the cloud and real time monitoring of blood tests.
Siemens Healthineers
Siemens Healthineers, through immunoassay and hematology analyzers, ensures accuracy of disease diagnosis. The company prioritizes AI-driven machine laboratory automation and precision medical care. It is seeing good traction in mature and emerging markets. New purchases have refurbished its capacity to tailor next-gen diagnostic tools for the particular needs of healthcare that are yet to be developed.
Danaher Corporation
Danaher Corporation is the molecular blood testing solutions provider with a distinctive logo of biomarker-based diagnostics. The company dedicates resources into tailor-made diagnostics that cater to the demands of precision medicine. The list of Danaher includes next-gen sequencing technology and tools for early disease detection. The company further expands through takeovers and strategic alliances.
Thermo Fisher Scientific
Thermo Fisher Scientific is a key player in laboratory-based blood diagnostics and reagent solutions. The company is the leader in clinical research tools and liquid biopsy innovations for the non-invasive testing market. It aims to improve early disease detection through its investment in precision medicine. Collateral strategic resources with health institutions are creating a stronger market presence.
Mid-sized and emerging firms have also contributed significantly in evolving blood testing technologies. These companies operate through specialized diagnostic equipment, which is more pocket-friendly, and by entering the untapped markets. Their contributions range from broadening product offerings to increasing access to novel testing solutions across various healthcare settings. A few such entities are:
The Blood Testing Equipment Market can be segmented based on:
The market is estimated to reach a value of USD 96.8 billion by the end of 2025.
The market is projected to exhibit a CAGR of 6.8% over the assessment period.
The market is expected to clock revenue of USD 135.0 billion by end of 2035.
Key companies in the Automated Test Equipment market include Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Danaher Corporation, Thermo Fisher Scientific.
On the basis on end use, Hospitals & Clinics to command significant share over the forecast period.
| Expected Market Value (2022) | USD 1.9 Billion |
|---|---|
| Anticipated Forecast Value (2032) | USD 2.8 Billion |
| Projected CAGR (2022 to 2032) | 4% |
| Expected Market Value (2022) | USD 19 Billion |
|---|---|
| Anticipated Forecast Value (2032) | USD 35 Billion |
| Projected CAGR (2022 to 2032) | 6.3% |
Explore Medical & Biomedical Instruments Insights
View Reports
Blood Testing Equipment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
